1537 ET - Medpace's better-than-expected earnings and revenue may not last for long, say Jefferies analysts David Windley and Tucker Remmers. Most of Medpace's 2Q revenue gains came from "pass-throughs," or repriced site costs in existing projects instead of new contracts, the analysts say, while revenue was also boosted by an all-time high backlog conversion rate. In 2023, the company similarly posted revenue gains boosted by pass-throughs and investors found out later that real bookings and awards were actually slowing, the analysts say. That lesson plus current volatility in biotech funding and increasing competition suggests that Medpace's success may only be short-term. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
July 22, 2025 15:37 ET (19:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。